Dr. Karen Rascati

Phone: (512) 471-1637
Fax: (512) 471-8762

krascati@mail.utexas.edu

Current Position:

Karen L. Rascati, RPh, PhD, is the Eckerd/Turley Centennial Professor of Pharmacy Administration and a faculty member of the Center for Pharmacoeconomic Studies at the University of Texas College of Pharmacy. She received her Pharmacy degree from the University of Florida in 1979 and worked as a pharmacist in both community and hospital settings. She returned to the University of Florida and received her PhD degree in Pharmacy Administration in 1986, with a concentration in health care policy and economics. Upon graduation, she joined the University of Texas, where she has won the Texas Excellence Teaching Award and serves as faculty advisor to both the Rho Chi Pharmacy Honor Society and the International Society of Pharmacoeconomics Outcomes and Research (ISPOR) student chapter. She was recently elected President-elect of the National Rho Chi Honor Society. She has supervised 28 MS and 13 PhD students.

Dr. Rascati has been elected to numerous offices within the American Pharmaceutical Association (APhA) Science Section and was recognized as a 1999 APhA Fellow (FAPhA). She is a charter member of ISPOR where she has served in many capacities. She served as a member of the ISPOR Board of Directors (1999-2001), Chair of the Education Committee (2001-2006) and was recently elected Treasurer (2007-2010).

Research Interests:

Dr. Rascati's research interests include economic and outcomes evaluations for several disease states as well as for pharmacy services. She has conducted over 30 funded research projects and has served on various grant review panels (including the National Institutes of Health [NIH]). She serves as a reviewer for many research journals and is a member of the Clinical Therapeutics Editorial Advisory Board. She has authored or co-authored more than 60 publications and over 100 presentations. Her book on Pharmacoeconomics is scheduled for release by Lippincott, Williams, and Wilkins (LWW) in Spring 2008.

Selected Recent Publications

  1. Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM. Comparison of Events (Hospitalizations and Emergent Department Visits) and Costs for Medicaid Patients with Chronic Obstructive Pulmonary Disease (COPD) by Initial Medication Regimen. Accepted by Clinical Therapeutics, Summer 2007.

  2. Nwokeji E, Rascati K, Moczegemba L, Wilson J. Pharmacoepidemiology Education in U.S. Colleges of Pharmacy. Accepted by the American Journal of Pharmaceutical Education, 2007.

  3. Rascati KL. The $64,000 question--what is a quality-adjusted life-year worth? Clinical Therapeutics; Vol. 28 (7), pp. 1042-1043. 2006

  4. Motsko, SP, Rascati, KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, and Worchel J. Temporal Relationship Between Use of NSAIDs, Including Selective Cox-2 Inhibitors, and Cardiovascular Risk . Drug Safety Vol. 29 (7): 621-632, 2006.

  5. Patel, NC, Crismon ML, Hoagwood K, Johnsrud MJ, Rascati KL, and Wilson JP. Physician Specialty Associated with Antipsychotic Prescribing for Youths in the Texas Medicaid Program. Medical Care, Volume 44, No. 1, pg 87-90, 2006.

  6. Rascati KL, Stanford R, Borker BS. A Comparison of the Risk of Hospitalizations Due to COPD in Medicaid in Medicaid Patients with Various Medication Regimens. Clinical Therapeutics Vol 27 (3), p 346-354, 2005.

  7. Nwokeji ED and Rascati KL Pharmacoeconomic Education in International Colleges of Pharmacy. American Journal of Pharmaceutical Education. Vol. 69 (3), p. 348-354, 2005.

  8. Smith MJ, Rascati KL, and Barner JC.Ý A Descriptive Analysis of Asthma-related Medical Services and Prescription Utilization Among Recipients in a Medicaid Program. Journal of Asthma. Vol. 42 (6): p. 447-453, 2005

  9. Patel NC, Crismon ML,Ý Hoagwood KE, Johnsrud MT, Rascati KL, Wilson JP.Ý Trends in antipsychotic prescribing to children and adolescents Journal of the American Academy of Child and Adolescent Psychiatry Vol 44, No. 6, p 548-556, 2005.

  10. Rascati KL, Drummond MF, Annemans, L Davey, PG. Education in Pharmacoeconomics: An International Multidisciplinary View. PharmacoEconomics, Vol 22(3), p 139-147, 2004.

  11. Smith MJ, Rascati KL, McWilliams B.Ý Inhaled Anti-inflammatory Pharmacotherapy and Subsequent Hospitalizations and Emergency Department Visits Among Patients with Asthma in the Texas Medicaid Program.Ý Annals Allergy Asthma Immunol., Vol 92,Ý p 40-46, 2004.

  12. Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, and Barber BL. Olanzapine Versus Risperidone in the Treatment of Schizophrenia: A Comparison of Costs Among Texas Medicaid Patients.PharmacoEconomics Vol 21 (10), pg. 683-697, 2003.

  13. Opolka JL, Rascati KL, Brown CM, and Gibson PJ Role of Ethnicity in predicting antipsychotic medication adherence. Annals of Pharmacotherapy Vol 37, pg. 625-630, 2003.

  14. Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MJ, and Gibson PJ. Ethnic Differences in Use of Antiphychotic Medication Among Texas Medicaid Clients with Schizophrenia. Journal of Clinical Psychology, Vol 64(6), pg. 635-639, 2003.

  15. Balkrishnan R, Camacho FT, Smith BP, Shilt JS, Jacks LK, Koman LA, Rascati KL. (3)Cost impact of botulinum toxin therapy in Medicaid-enrolled children with cerebral palsy. Journal of Southern Orthopedic Association 11 (2): 71-82, 2002.

  16. Smith MJ, Rascati KL, Johnsrud MT. Costs and Utilization Patterns Associated With Persistent Asthma: A Comparison of Texas Medicaid Clients With and Without Inhaled Corticosteroid Treatment. Journal of Managed Care Pharmacy . Vol. 7 (6) Nov/Dec 2001, p. 452-459.

  17. Rascati KL, Godley P, and Pham H. Evaluation of Resources Used to Treat Adverse Events of SSRI Use. Journal of Managed Care Pharmacy Vol. 7 (5) Sept/Oct 2001, p. 402-406.

  18. Rascati KL, Smith MJ, Neilands T. Dealing With Skewed Data: An Example Using Asthma Related Medicaid Costs. Clinical Therapeutics , Vol. 23 (3). March 2001, p. 481-498.

  19. Wilson JP, Bulatao PT and Rascati KL. Pharmacy and Provider Satisfaction with Practitioner Order Entry (POE) using the Composite Health Care System (CHCS). American Journal of Health-System Pharmacy , Vol. 57, Dec 1, 2000, p. 2188-2195.

  20. Rascati KL and Gagnon JP. Pharmacoeconomics Education, Managed Care and the Pharmaceutical Industry. American Journal of Pharmaceutical Education , Vol. 63, Winter 1999, p. 449-453.

  21. Malone DC, Rascati KL, Martin J. An Analysis of the Product Liability Costs Borne by Prescription Drug Manufacturers. Research in Finance, Vol. 17, 1999, p 173-190.

  22. Khan ZM, Rascati KL, Koeller JM, Smeeding J. FAX Technology in Collecting Outcomes Data in a Computer Database. American Journal of Health-System Pharmacy , Dec 15 1999, Vol. 56, p. 2540-2542.

  23. Marsh WA and Rascati KL. Meta-Analysis of the Effectiveness of Erythropoietin for End-Stage Renal Disease and Cancer. Clinical Therapeutics , Vol. 21(9), September 1999, p. 1443-1455.

  24. Khan ZM, Rascati KL, Koeller JM. Economic Analysis of Carboplatin Versus Cisplatin in Lung and Ovarian Cancer. PharmacoEconomics , Vol. 16 (1), July 1999, p. 43-57.

  25. Okano GJ, Rascati KL, Wilson JP, and Remund DD. A Comparison of Antihypertensive Medication Utilization Before and After Guideline Changes Using the Department of Defense Prescription Database. Annals of Pharmacotherapy , Vol. 33, May 1999, p. 548-53.

  26. Rascati KL, Draugalis JR, and Conner TM. Pharmacoeconomic Education in U.S. Schools of Pharmacy. American Journal of Pharmaceutical Education , Vol. 62 (2), Summer 1998, p. 167-169

  27. Rascati KL. Practical Aspects of Using Personal Computers for Decision-Analytic Modeling. Drug Benefit Trends , Vol. 10 (7), July 1998, p. 33-36.

  28. Rascati KL, Okano GJ and Burch C. Evaluation of Physician Intervention Letters. Medical Care , Vol. 34 (8), August 1996, p. 760-766.zz,

Book Chapters

  1. Barner JC, Rascati KL. Cost-Benefit Analysis. Chapter 8 in Pharmacoeconomics and Outcomes: Applications for Patient Care . American College of Clinical Pharmacy (AACP). Kansas City MO, 2003.

  2. Vincze G, Rascati KL, Vincze Z. Health-Related Quality of Life. Chapter 11 in Introduction to Pharmacoeconomics (Bevezetes A Farmako-Okonomiaba). Budapest, Hungary, 2001.

  3. Rascati KL. Pharmacoeconomics - Learning Unit in Pharmacy & Managed Care , Fall 2000.

  4. Wilson J and Rascati KL. Introduction to Pharmacoeconomics. Chapter in Drug Information: A Guide for Pharmacists , 2nd Ed., McGraw Hill, 2000.

  5. Rascati KL, Draugalis J, and Conner T. Pharmacoeconomic Education in Schools of Pharmacy. Chapter in Pharmacoeconomics and Outcome Assessment: A Global Issue , editor S. Salek, Euromed Communications Ltd, 1999.

Select Recent Invited Presentations

  1. Retrosepctive Database Analysis: The Good, the Bad, and the Ugly. University of Southern California Pharmacy Graduate Seminar, Los Angeles, CA, January, 2007.

  2. Rascati KL. Texas Medicaid: Compliance with Atypical Anti-psychotics. The Second Annual Medicaid Summit. Park City Utah October 2005.

  3. Rascati. CV Writing Workshop. ISPOR International Teleconference Student Workshop May 2005.

  4. Rascati KL, Stanford R, Borker BS. Comparison of Hospitalization for Medicaid Patients with Chronic Obstructive Pulmonary Disease by Initial Medication Regimen. The Medicaid Summit. Park City Utah Sept.2004.

  5. Rascati KL. Overview of Graduate Student Research. St. Louis College of Pharmacy, St. Louis, Missouri, February 2004.

  6. Analysis of the Costs of Treatment with Atypical Anti-psychotic Agents: Results from a Texas Medicaid Study, Health Outcomes Consumer Feedback Forum, New Orleans, LA May 2003.

  7. Research in Pharmacy: Emphasizing Outcomes, Annual Robert Boblitt Rho Chi Lecture. University of Houston, Houston TX, September 2002.

  8. Pharmacoeconomic Outcomes in the Treatment of Schizophrenia. APhA satellite symposium. Philadelphia PA, March 2002.

  9. Modeling the Decision Making Process for Anti-hypertensive Therapy. Co-presenters C. Daniel Mullins and Kasem Akhras. Pharmacia Health Outcomes Working Group, Toronto, Canada, November 2001.

  10. Pharmacoeconomics Research Workshop. Dallas Texas, November 2001.

  11. Beyond Efficacy: Evaluating Humanistic and Societal Outcomes in the Mentally Ill. Panel Session for the Beam Institute, Colorado Springs CO, September 2001.

  12. Pharmacoeconomics and Outcomes Research. Faculty and Graduate Students at UNC College of Pharmacy, Chapel Hill NC, August 2001.

  13. Trends in Data Evaluation by Managed Care. Pharmacia Health Outcomes Working Group Meeting, Carmel Valley CA, April 2001.

  14. Establishing the Legitimacy of Claims Data (with Pathak and O1Donnell). The Value of Economic Research in Medical Decision Making Conference, Phoenix AZ, February 2001.

  15. Are Decision Makers Using Pharmacoeconomic Information: Evidence from the Literature. University of Arizona Conference, Tucson AZ, February 2000.

  16. Coordinator and presenter for: Pharmacoeconomic Education, Managed Care and the Pharmaceutical Industry - A Panel Discussion. American Association of Colleges of Pharmacy (AACP) Annual meeting, Boston MA, July 1999.

  17. Decision Analysis to Treat Depression Workshop. Controversies in Health Care: Balancing Patient Care Decision and Drug Therapy Costs, Veteran1s Affairs Medical Center, Albuquerque NM, June 1999.

  18. Pharmacoeconomics Workshop. MedEcon, Dallas TX, September 1998.

  19. An Overview of Recent Research Projects. University of Florida Graduate Student Seminar, Gainesville FL, January 1998.

  20. Decision Analytic Modeling Workshop (with Lee Fleisher M.D), Association for Pharmacoeconomics and Outcomes Research Annual Meeting, Philadelphia PA, April 1997.

Selective Recent Research Presentations

  1. Nwokeji E, Rascati KL, Brown CM. Examining Family Physiciansí Attitudes and Willingness to Prescribe Long-Acting Opiods to Patients with Moderate to Severe Chronic Non-malignant Pain. ISPOR Annual Meeting, Arlington VA, May 2007.

  2. Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM. Comparison of Events (Hospitalizations and Emergency Department Visits) and Costs for Medicaid Patients with Chronic Obstructive Pulmonary Disease (COPD) by Initial Medication Regimen. ISPOR Annual Meeting, Arlington VA, May 2007.

  3. Prasla K, Godley P, Gabrillo E, Rascati KL. Medication Adherence in Patients with Diabetes During the Medicare Part D Benefit Coverage Gap Period. ISPOR Annual Meeting, Arlington VA, May 2007.

  4. Nwokeji E, Rascati KL, Brown CM. Examining Texas Family Physicians' Attitudes and Beliefs Toward Prescribing Long-acting Opioids for Chronic Non-malignant Pain. American Pain Society, Washington DC, May 2007.

  5. Rascati, KL, Akazawa, M, Stanford RH, Johnsrud, M. Comparison of Medical and Prescription Costs for Medicaid Patients with COPD by Initial Medication Regimen. Academy of Managed Care Pharmacy (AMCP) Annual Meeting, San Diego, April 2007

  6. Rascati, KL, Akazawa M, Stanford RH, Johnsrud M. Risk of Hospitalizations and/or Emergency Department Visits for Medicaid Patients with COPD: Comparison of Controllers. ISPOR Annual European Meeting, Copenhagen, Denmark, October 2006. (Poster Finalist Award).

  7. Rascati, KL, Akazawa, M, Stanford RH. Risk of Hospitalizations and/or Emergency Department Visits for Medicaid Patients with COPD: Comparison of Controllers. CHEST 2006, Salt Lake City, Utah, October 2006.

  8. Nwokeji, E, Rascati K, Wilson J, Moczegemba L. Extent of Pharmacoepidemiology Education in U.S. Schools of Pharmacy. International Society for Pharmacoepidemiology. Lisbon Portugal, August 2006.

  9. Nwokeji, E, Rascati K, Wilson J, Moczegemba L. Pharmaceoepidemiology Education in US Colleges of Pharmacy. American Association of Colleges of Pharmacy (AACP) Annual meeting, San Diego, CA, July 2006.

  10. Yang M, Barner JC, Lawson KA, Rascati KL, Crismon ML, Wilson JP, Worchel J, Mascarenas C. Antipsychotic Utilization and Treatment-emergent Diabetes - Comparison of Results With and Without Propensity Scoring.ISPOR Annual Meeting, Philadelphia PA, May 2006.

  11. Harrington P, Barner J, Crismon ML, Lawson K, Mascarenas C, Rascati KL. Demographic and Clinical Characteristics of Patients Prescribed Antipsychotic (AP) Monotherapy in Texas Medicaid.ISPOR Annual Meeting, Philadelphia PA, May 2006.

  12. Harrington P, Barner J, Crismon ML, Lawson K, Mascarenas C, Rascati K. Incident Diabetes Associated with Use of Second-Generation Antipsychotic (SGA) Therapy: An Evaluation of the Impact of Dose and Treatment Indication. ISPOR Annual Meeting, Philadelphia PA, May 2006.

  13. Rascati, K, Ngan G, Godley P Omar M. Post-Fracture Follow-up and Medication Utilization Pattern of Patients with Osteoporotic Fractures in a Managed Care Health Care System, Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Seattle WA, April 2006.

  14. Conner TM, Bolster SR, Rankin S, Inman GM, Rascati KL. Costs Associated with Glucose Control in the Non-diabetic Critically Ill Patients. ISPOR Annual European Meeting, Florence Italy, November 2005.

  15. Bolster SR, Conner TM, Rankin S, Inman G, Rascati KL. Costs Associated with a Continuous Insulin Infusion Protocol in Critical Care. American College of Clinical Pharmacy (ACCP) Annual Meeting, San Francisco CA, October 2005.

  16. Motsko, SP, Rascati KL, Busti AJ. Wilson JP,. Barner JC, Lawson KA, Worchel J. Temporal Relationship Between Long-term Use of NSAIDs / COX- 2 Inhibitors and Cardiovascular Risk: A Retrospective Analysis Using the Veteranís Affairs (VA) Database. International Society for Pharmacoepidemiology, Annual Meeting, Memphis, TENN, August 2005.

  17. Tiller KW, Rascati KL. Wilson JP. Alendronate and Hormone Replacement Therapy (HRT) in the Prevention of Osteoporotic Fracture in the Department of Defense (DOD): An Analysis using Net-Benefit Regression. ISPOR Annual Meeting Washington DC ,May 2005

  18. Motsko, SP, Rascati KL, Barner JC Busti AJ, Lawson KA, Wilson JP. Association Between Long-term Use of NSAIDs / COX- 2 Inhibitors and Cardiovascular Risk: A Retrospective Analysis Using the Veteranís Affairs (VA) Database. ISPOR Annual Meeting, Washington DC, May 2005.

  19. Nwokeji ED and Rascati KL. Pharmacoeconomic Education at Non-US Colleges of Pharmacy. ISPOR Annual European Meeting, Hamburg, Germany, October 2004. [Won Student Podium Presentation Award]

  20. Crismon ML, Patel NC, Hoagwood KE, Johnsrud MT, Rascati KL, Wilson JP.Ý Trends in antipsychotic prescribing to children and adolescents: 1996 to 2001.Ý NIMH Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ JuneÝ 2004.

  21. Patel NC, Crismon ML, Hoagwood KE, Johnsrud MT, Rascati KL, Wilson JP.Ý Trends in antipsychotic prescribing to children and adolescents: 1996 to 2001. ISPOR Annual International Meeting, Arlington, VA, May 2004.

  22. Conner T, Drosu D, Krstic B, Rankin S, Newby C, Rascati K, Flesner K, Weingarten J., Intensivist Practice Change in Glucose Control for Critically Ill Patients, ISPOR Annual European Meeting, Barcelona, Spain, November 2003.

  23. Harrington, P and Rascati, KL, Johnsrud M. Evaluation of Medical Diagnoses for Texas Medicaid Patients Prescribed Atypical Antipsychotic Medications. ISPOR Annual European Meeting, Barcelona, Spain, November 2003

  24. Rascati KL, Stanford R, Borker BS. Comparison of Hospitalization Risk for Medicaid Patients with Chronic Obstructive Pulmonary Disease by Medication Regimen. European Respiratory Society (ERS) Conference, Vienna, Austria, September 2003.

  25. Smith MJ and Rascati KL. A Descriptive Analysis of Asthma-related Prescription and Medical Service Utilization Among Patients in the Texas Medicaid Program. National Conference on Asthma Management. Washington D.C. June 2003

  26. Smith MJ and Rascati KL. The Relationship Between Inhaled Anti-inflammatory Pharmacotherapy and Subsequent Hospitalization Among Children with Asthma. National Conference on Asthma Management. Washington D.C. June 2003

  27. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and Schizophrenia Medication Choice: Haloperidol, Risperidone, or Olanzapine. American College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum. Palm Springs, CA, April 2003.

  28. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and Schizophrenia Medication Choice: Haloperidol, Risperidone, or Olanzapine American Psychiatric Association (APA) Annual Meeting . San Francisco, CA, May 2003, and ISPOR Annual Meeting .Arlington, VA, May 2003.

  29. Rascati KL, Stanford R, Borker BS. Comparison of Risk for Hospital and/or ED Visits for Medicaid Patients with COPD. ISPOR Annual Meeting, Arlington VA, May 2003.

  30. Rascati KL, Stanford R, Borker BS. Comparison of Hospitalization Risk for Medicaid Patients with Chronic Obstructive Pulmonary Disease by Medication Regimen. American Thoracic Society, Seattle, Washington, May 2003.

  31. Vincze G, Yeh JY, Conner C, Rascati KL. Information-Seeking Patterns in Diabetes. Texas Society of Health-System Pharmacists. Arlington, TX, April 2003.

  32. Smith MJ and Rascati KL. Inhaled Cortico-steroid Use and Risk of Asthma-related Near-fatal Events Among Adult Recipients with Asthma in the Texas Medicaid Program. American Pharmaceutical Association Annual Meeting, New Orleans LA, March, 2003

  33. Monroe DM and Rascati. Clinical Effectiveness of Tolterodine Versus Oxybutin for the Treatment of Overactive Bladder in Elderly Nursing Home Rresidents. American Society of Consultant Pharmacists 33rd Annual Meeting Anaheim CA, November 2002.

  34. Smith MJ and Rascati KL. Inhaled Anti-inflammatory Medication Use and Subsequent Hospitalizations Among Texas Medicaid Patients with Persistent Asthma. ISPOR Annual European Meeting, Rotterdam, The Netherlands, November 2002.

  35. Opolka JL, Rascati KL, Brown CM, Gibson PJ. The Effects of Ethnicity and Antipsychotic Type on Medication Adherence in a Medicaid Population. ISPOR Annual European Meeting, Rotterdam, The Netherlands, November 2002.

  36. Conner TM, Limerick M, and Rascati KL. Evaluation of a Palliative Care Team on Resource Utilization in an Acute Care Setting. ISPOR Annual European Meeting, Rotterdam, The Netherlands, November 2002.

  37. Monroe DM, Rascati KL. Urinary Incontinence Evaluations in Nursing Home Facilities in Texas. ISPOR Annual European Meeting, Rotterdam, The Netherlands, November 2002.

  38. Opolka JL, Rascati KL, Brown CM, Gibson PJ. The Effects of Ethnicity and Antipsychotic Type on Medication Adherence in a Medicaid Population. American College of Clinical Pharmacy (ACCP) Annual Meeting. Albuquerque, NM October 2002

  39. Rascati KL and Conner TM. Comparison of Adverse Drug Events (ADEs) Associated with SSRIs in Two Managed Care Organizations. ISPOR Annual European Meeting, Cannes France, November 2001.

  40. Rascati KL. Frequency and Costs of Side Effects with SSRI Use. World Congress of Biological Psychiatry, Berlin, Germany, July 2001.

  41. Rascati KL, Johnsrud MT, Crismon ML, Barber BL, and Lage MJ. Olanzapine Versus Risperidone in the Treatment of Schizophrenia: A Comparison of Costs Among Texas Medicaid Patients. ISPOR Annual Meeting, Arlington VA, May, 2001.

  42. Rascati KL, Barber BL, and Lage MJ. A Comparison of Schizophrenia-related Costs and Total Costs Among Texas Medicaid Patients. American Psychiatric Association Meeting, New Orleans LA, May 2001.

  43. Rascati KL. Comparison of Side Effects of SSRIs. Academy of Managed Care Pharmacy. Tampa FL, April 2001.

  44. Rascati KL. Costs of Treating Side Efects of SSRIs in an HMO. ISPOR Annual European Meeting, Antwerp, Belgium, November 2000.

  45. Hunter JA, Rascati KL, and Salzman RD. Robotic Technology Effects in a 525-Bed Hospital. Pharmacy Administration Conference 2000, Austin TX, June 2000.

  46. Rascati KL and Smith MJ. Dealing with Skewed Data: An Example Using Asthma Related Costs of Medicaid Clients. ISPOR Annual Meeting, Washington D.C., May 2000.

  47. Smith MJ, Rascati KL. Use of Inhaled Corticosteroids to Treat Texas Medicaid Clients with Asthma: Assessment of Prescriptions and Medical Service Payments. APhA Annual Meeting, Washington D.C., March 2000.

Pharmacy Practice and Administration: Description | Faculty | Related Links | Admission
April 18, 2007
Faculty Directory
College of Pharmacy at UT Austin
Comments to: pharmacy@www.utexas.edu 		Pharmacy